According to the American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline, the patient’s HER2 status was classified as 2+, with negative FISH results, consistent with a diagnosis of low HER2 expression in breast cancer (19). This evidence concerns the gene ERBB2 and breast carcinoma.